Patients with epidermodysplasia verruciformis show no response to contact immunotherapy.
Ishiji
T
T
Ibe
M
M
Kawase
M
M
Niimura
M
M
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D003503:Cyclobutanes / Q000627:therapeutic use; D004279:DNA, Viral / Q000032:analysis / Q000235:genetics; D004137:Dinitrochlorobenzene / Q000627:therapeutic use; D004819:Epidermodysplasia Verruciformis / Q000276:immunology / Q000628:therapy*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D027383:Papillomaviridae / Q000235:genetics; D030361:Papillomavirus Infections / Q000276:immunology / Q000628:therapy; D012867:Skin / Q000473:pathology* / Q000821:virology; D016896:Treatment Outcome; D014412:Tumor Virus Infections / Q000276:immunology / Q000628:therapy
D000276:Adjuvants, Immunologic; D003503:Cyclobutanes; D004279:DNA, Viral; D004137:Dinitrochlorobenzene; C020637:squaric acid dibutyl ester